855527-92-3

Usage

Uses

Used in Pharmaceutical Industry:
NBI-74330 is used as a CXCR3 antagonist for the treatment of various inflammatory and immune-related conditions. Its ability to inhibit chemotaxis and reduce inflammation makes it a potential candidate for the development of therapeutic agents targeting diseases such as atherosclerosis, peritonitis, and neuropathic pain.
Used in Research Applications:
NBI-74330 is used as a research tool for studying the role of CXCR3 in various biological processes and disease mechanisms. Its high affinity and selectivity for CXCR3 make it a valuable compound for investigating the molecular and cellular functions of this receptor in both in vitro and in vivo experimental models.

Upstream product

• 156-43-4 4-Ethoxyaniline 
• 947536-07-4 C₂₂H₂₆N₄O₄ 
• 947536-13-2 rac-2-(1-amino-ethyl)-3-(4-ethoxy-phenyl)-3H-pyrido[2,3-d]pyrimidin-4-one 
• 220227-47-4 (4-fluoro-3-trifluoromethyl-phenyl)-acetic acid 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 752244-95-4 (R)-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-carbamic acid tert-butyl ester 
• 473720-90-0 (R)-{1-[3-(4-ethoxy-phenylcarbamoyl)-pyridin-2-ylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 473720-89-7 (R)-[1-(4-oxo-4H-pyrido[2,3-d][1,3]oxazin-2-yl)-ethyl]-carbamic acid tert-butyl ester 
• 947536-02-9 rac-3-(4-ethoxy-phenyl)-2-{1-[(pyridin-3-ylmethyl)-amino]-ethyl}-3H-pyrido[2,3-d]pyrimidin-4-one 
• 473720-92-2 C₂₃H₂₃N₅O₂ 

Downstream Products

• 1002962-60-8 C₃₂H₂₇F₄N₅O₄ 

Relevant academic research and scientific papers

Synthesis and Application of the First Radioligand Targeting the Allosteric Binding Pocket of Chemokine Receptor CXCR3

Strategies for the identification of allosteric modulators of chemokine receptors largely rely on various cell-based functional assays. Radioligand binding assays are typically not available for allosteric binding sites. We synthesized, purified, and appl

Optimization of a series of quinazolinone-derived antagonists of CXCR3

The evaluation of the CXCR3 antagonist AMG 487 in clinic trials was complicated due to the formation of an active metabolite. In this Letter, we will discuss the further optimization of the quinazolinone series that led to the discovery of compounds devoi

Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists

CXC chemokine receptor-3 (CXCR3) is a G-protein coupled receptor (GPCR) predominantly expressed on activated T lymphocytes that promote Th1 responses. Previously, we described the 3H-quinazolin-4-one containing VUF 5834 (decanoic acid {1-[3-(4-cyano-pheny